| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
24,25-Dihydroxy VD2 targets the vitamin D receptor (VDR) and related signaling pathways involved in calcium and phosphate homeostasis. As a metabolite of vitamin D2, it plays a role in the regulation of calcium and phosphate metabolism. The compound has some bone calcium mobilizing activity and stimulates intestinal calcium transport. It is an intermediate in the vitamin D metabolic pathway.
|
|---|---|
| ln Vitro |
In vitro, 24,25-Dihydroxy VD2 has some bone calcium mobilizing activity and stimulates intestinal calcium transport. As a hydroxylated metabolite of vitamin D2, its biological activity is characterized in cell-based assays measuring VDR activation, calcium transport, and gene expression changes. The compound's activity is typically lower than that of the active form 1,25-dihydroxyvitamin D, reflecting its role as a metabolic intermediate.
|
| ln Vivo |
In vivo, 24,25-Dihydroxy VD2 has some bone calcium mobilizing activity and stimulates intestinal calcium transport. As a metabolite of vitamin D2, it is produced in the body and plays a role in regulating calcium and phosphate metabolism. The compound is a synthetic vitamin D analog used in research to study vitamin D metabolism and function. Its effects on bone and calcium homeostasis have been characterized in animal models.
|
| Enzyme Assay |
The in vitro receptor binding assay for 24,25-Dihydroxy VD2 involves measuring its affinity for the vitamin D receptor (VDR). Purified VDR or cell lysates from VDR-expressing cells are incubated with radiolabeled 1,25-dihydroxyvitamin D3 (e.g., 3H-1,25(OH)2D3) and varying concentrations of 24,25-Dihydroxy VD2 (typically 0.001 nM to 10 uM) in binding buffer at 4degC for 2-4 hours. Bound and free ligand are separated by charcoal adsorption or hydroxyapatite chromatography, and radioactivity is measured by scintillation counting. The relative binding affinity is calculated from competition curves.
|
| Cell Assay |
In vitro cellular assays for 24,25-Dihydroxy VD2 are conducted using VDR-expressing cell lines such as osteoblasts, intestinal epithelial cells, or kidney cells. Cells are seeded in multi-well plates and treated with varying concentrations of 24,25-Dihydroxy VD2 (typically 0.01 nM to 10 uM) for 24-48 hours. VDR activation is assessed by measuring the expression of VDR target genes (e.g., CYP24A1, osteocalcin) by qPCR. Calcium transport is measured in intestinal epithelial cell models using radioactive ⁴⁵Ca or fluorescent calcium indicators. Cell viability is monitored using MTT or similar assays.
|
| Animal Protocol |
In vivo animal studies for 24,25-Dihydroxy VD2 typically involve administration to rodents to assess its effects on calcium and phosphate metabolism. The compound is administered by oral gavage or intraperitoneal injection at doses ranging from 0.01-10 ug/kg/day for 1-4 weeks. Serum calcium, phosphate, and vitamin D metabolite levels are measured. Bone mineral density is assessed by DEXA or micro-CT. Intestinal calcium transport is measured using everted gut sac assays or by assessing calcium absorption using radioactive tracers. At study termination, tissues are harvested for histological examination and gene expression analysis.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 24,25-Dihydroxy VD2 are characteristic of a vitamin D metabolite. The compound has a molecular weight of 428.65 and a molecular formula of C28H44O3. It has a computed XLogP3-AA of 5.7. The compound is insoluble in water (8.3E-4 g/L at 25degC). As a lipophilic compound, it is typically formulated in oil-based or organic solvent-based vehicles for in vivo administration. The compound is metabolized to other vitamin D metabolites and excreted primarily via bile and feces.
|
| Toxicity/Toxicokinetics |
The toxicological profile of 24,25-Dihydroxy VD2 is characteristic of vitamin D metabolites. At high doses, vitamin D compounds can cause hypercalcemia and soft tissue calcification. The compound is for research use only and is not intended for human therapeutic use. Standard safety precautions should be followed when handling the compound. No specific LD50 values have been reported. The compound should be stored under appropriate conditions as recommended by the supplier.
|
| References |
|
| Additional Infomation |
(24R)-24,25-Dihydroxyvitamin D2/(24R)-24,25-Dihydroxyergocalciferol is a vitamin D.
See also: 24,25-Dihydroxyvitamin D2 (note moved to). 24,25-Dihydroxy VD2 (CAS 58050-55-8) is a hydroxylated metabolite of vitamin D2 and a synthetic vitamin D analog. It has some bone calcium mobilizing activity and stimulates intestinal calcium transport. The compound is produced in the body from 25-hydroxyvitamin D and is used in research to study vitamin D metabolism and function. It is available for research purposes only. |
| Molecular Formula |
C28H44O3
|
|---|---|
| Molecular Weight |
428.64716
|
| Exact Mass |
428.329
|
| CAS # |
58050-55-8
|
| PubChem CID |
9547251
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.87
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
31
|
| Complexity |
773
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C[C@H](/C=C/[C@](C)(C(C)(C)O)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C
|
| InChi Key |
BPEQZNMKGFTMQE-LXHCYJFYSA-N
|
| InChi Code |
InChI=1S/C28H44O3/c1-19-9-12-23(29)18-22(19)11-10-21-8-7-16-27(5)24(13-14-25(21)27)20(2)15-17-28(6,31)26(3,4)30/h10-11,15,17,20,23-25,29-31H,1,7-9,12-14,16,18H2,2-6H3/b17-15+,21-10+,22-11-/t20-,23+,24-,25+,27-,28-/m1/s1
|
| Chemical Name |
(E,3R,6R)-6-[(1R,3aS,4E,7aR)-4-[(2Z)-2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2,3-dimethylhept-4-ene-2,3-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~233.29 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3329 mL | 11.6645 mL | 23.3291 mL | |
| 5 mM | 0.4666 mL | 2.3329 mL | 4.6658 mL | |
| 10 mM | 0.2333 mL | 1.1665 mL | 2.3329 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
